Your session is about to expire
← Back to Search
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 30 days post participant's last study treatment
Awards & highlights
Summary
The purpose of this study is to evaluate the effects of BMS-986371 on the drug levels of methotrexate, sulfasalazine and their main metabolites in healthy male adult participants.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 30 days post participant's last study treatment
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 30 days post participant's last study treatment
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC[INF])
Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUC[0-T])
Maximum observed plasma concentration (Cmax)
Secondary outcome measures
AUC(0-T)
AUC(INF)
Cmax
+1 moreTrial Design
2Treatment groups
Experimental Treatment
Group I: Part 2Experimental Treatment4 Interventions
Group II: Part 1Experimental Treatment3 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
BMS-986371
2022
Completed Phase 1
~30
Leucovorin
FDA approved
Sulfasalazine
FDA approved
Methotrexate
FDA approved
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Bristol-Myers SquibbLead Sponsor
2,652 Previous Clinical Trials
4,130,719 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger